One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma
This poster presents follow-up data from the pivotal trial of brexucabtagene autoleucel (Tecartus) for mantle cell lymphoma showing that 75.1% of patients who achieve a CR following this CART, retain […]